First Transdermal Testosterone Gel to Significantly Increase Sexual Activity In Surgically Menopausal Women

First Transdermal Testosterone Gel to Significantly Increase
Sexual Activity In Surgically Menopausal Women
BioSante's LibiGel(TM) Shows 238% Increase in Frequency Of Satisfying Sexual
Events, According to Data at ISSWSH



LINCOLNSHIRE, Ill., Nov. 1  /PRNewswire-FirstCall/ -- BioSante Pharmaceuticals,
Inc. (AMEX:BPA) today announced the presentation of new Phase II clinical data
on LibiGel(TM) (transdermal testosterone gel) at the International Society for
the Study of Women's Sexual Health (ISSWSH) Annual Meeting in Atlanta (October
28-31).  Results show the ability of LibiGel to significantly increase the
number of satisfying sexual events experienced by surgically menopausal women
with female sexual dysfunction (FSD).

BioSante's Phase II study assessed the safety and efficacy of LibiGel in the
treatment of surgically menopausal women with FSD.  Results showed that LibiGel
150 mcg per day significantly increased the number of satisfying sexual events
by 238 percent versus baseline (from 2.1 events per month at baseline to 7.1
events during month three; p